TransMedics Group (NASDAQ:TMDX) Trading 8.1% Higher

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) were up 8.1% during trading on Tuesday . The company traded as high as $162.72 and last traded at $160.52. Approximately 481,062 shares changed hands during mid-day trading, a decline of 37% from the average daily volume of 759,574 shares. The stock had previously closed at $148.45.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on TMDX. Cantor Fitzgerald began coverage on shares of TransMedics Group in a report on Thursday, June 6th. They set an “overweight” rating and a $161.00 target price on the stock. JPMorgan Chase & Co. boosted their target price on shares of TransMedics Group from $105.00 to $127.00 and gave the stock an “overweight” rating in a report on Wednesday, May 1st. Morgan Stanley boosted their target price on shares of TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Oppenheimer boosted their target price on shares of TransMedics Group from $125.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, August 1st. Finally, Stephens boosted their target price on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $166.88.

TransMedics Group Stock Performance

The stock has a market capitalization of $5.33 billion, a price-to-earnings ratio of -470.50 and a beta of 1.99. The company’s fifty day simple moving average is $144.52 and its 200 day simple moving average is $112.74. The company has a quick ratio of 8.76, a current ratio of 9.72 and a debt-to-equity ratio of 3.18.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, beating the consensus estimate of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 17.37%. The firm had revenue of $114.30 million for the quarter, compared to the consensus estimate of $98.84 million. During the same period in the previous year, the company earned ($0.03) earnings per share. The company’s quarterly revenue was up 117.7% on a year-over-year basis. On average, equities research analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Activity at TransMedics Group

In related news, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $149.96, for a total value of $1,012,230.00. Following the transaction, the director now directly owns 732 shares in the company, valued at $109,770.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $149.96, for a total value of $1,012,230.00. Following the transaction, the director now directly owns 732 shares in the company, valued at $109,770.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David Weill sold 2,500 shares of the company’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $129.82, for a total transaction of $324,550.00. Following the completion of the transaction, the director now owns 11,193 shares in the company, valued at $1,453,075.26. The disclosure for this sale can be found here. Over the last three months, insiders have sold 55,671 shares of company stock worth $7,947,033. Corporate insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Several institutional investors and hedge funds have recently bought and sold shares of TMDX. Venturi Wealth Management LLC bought a new stake in TransMedics Group during the first quarter worth about $30,000. Fidelis Capital Partners LLC bought a new stake in TransMedics Group during the first quarter worth about $35,000. International Assets Investment Management LLC bought a new stake in TransMedics Group during the second quarter worth about $47,000. J.Safra Asset Management Corp lifted its holdings in shares of TransMedics Group by 649.2% in the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after acquiring an additional 383 shares during the last quarter. Finally, Signaturefd LLC lifted its holdings in shares of TransMedics Group by 26.6% in the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after acquiring an additional 93 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.